A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm
Latest Information Update: 25 Dec 2024
At a glance
- Drugs PM-8002 (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biotheus
Most Recent Events
- 01 Jun 2023 New trial record